Comparative prime-boost vaccinations using semliki forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 6761-6769

  Näslund, Tanja I ^a   Uyttenhove, Catherine ^b,c   Nordström, Eva K L ^a   Colau, Didier ^b,c   Warnier, Guy ^b,c   Jondal, Mikael ^a   Van Den Eynde, Benoît J ^b,c   Liljeström, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALVAC VECTOR; CD8 ANTIGEN; L SELECTIN; P1A TUMOR ANTIGEN; SEMLIKI FOREST VIRUS VECTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DBA 2 MOUSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; LYMPH NODE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SPLEEN; TUMOR; TUMOR IMMUNITY; TUMOR MODEL; VACCINATION; VACCINE PRODUCTION;

EID: 34249782279     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.6761     Document Type: Article

References (94)

1. Stevenson, F. K., J. Rice, and D. Zhu. 2004. Tumor vaccines. Adv. Immunol. 82: 49-103.
2. Dermime, S., A. Armstrong, R. E. Hawkins, and P. L. Stern. 2002. Cancer vaccines and immunotherapy. Br. Med. Bull. 62: 149-162.
3. Nayeem, M. S., and R. H. Khan. 2006. Recombinant antibodies in cancer therapy. Curr. Protein Pept. Sci. 7: 165-170.
4. Bonnet, M. C., J. Tartaglia, F. Verdier, P. Kourilsky, A. Lindberg, M. Klein, and P. Moingeon. 2000. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74: 11-25.
5. Ribas, A., L. H. Butterfield, J. A. Glaspy, and J. S. Economou. 2003. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21: 2415-2432.
6. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
7. Relph, K. L., K. J. Harrington, and H. Pandha. 2005. Adenoviral strategies for the gene therapy of cancer. Semin. Oncol. 32: 573-582.
8. Liu, M., B. Acres, J. M. Balloul, N. Bizouarne, S. Paul, P. Slos, and P. Squiban. 2004. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14567-14571.
9. Srivastava, P. K. 2006. Therapeutic cancer vaccines. Curr. Opin. Immunol. 18: 201-205.
10. Harrop, R., and M. W. Carroll. 2006. Viral vectors for cancer immunotherapy. Front. Biosci. 11: 804-817.
11. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
12. Warnier, G., M. T. Duffour, C. Uyttenhove, T. F. Gajewski, C. Lurquin, H. Haddada, M. Perricaudet, and T. Boon. 1996. Induction of a cytolytic T cell response in mice with a recombinant adenovirus coding for tumor antigen P.815A. Int. J. Cancer 67: 303-310.
13. Gallo, P., S. Dharmapuri, B. Cipriani, and P. Monaci. 2005. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther. 12(Suppl. 1): S84-S91.
14. Rosenberg, S. A., Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp 100 melanoma antigens. J. Natl. Cancer Inst. 90: 1894-1900.
15. Marshall, J. L., M. J. Hawkins, K. Y. Tsang, E. Richmond, J. E. Pedicano, M. Z. Zhu, and J. Schlom. 1999. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17: 332-337.
16. Ullenhag, G. J., J. E. Frodin, S. Mosolits, S. Kiaii, M. Hassan, M. C. Bonnet, P. Moingeon, H. Mellstedt, and H. Rabbani. 2003. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin. Cancer Res. 9: 2447-2456.
17. van Baren, N., M. C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V. G. Brichard, et al. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23: 9008-9021.
18. Spaner, D. E., I. Astsaturov, T. Vogel, T. Petrella, I. Elias, S. Burdett-Radoux, S. Verma, N. Iscoe, P. Hamilton, and N. L. Berinstein. 2006. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106: 890-899.
19. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 271; 907-913.
20. von Mehren, M., P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L. M. Weiner. 2000. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6: 2219-2228.
21. von Mehren, M., P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, S. McLaughlin, M. T. Beard, et al. 2001. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7: 1181-1191.
22. Marshall, J. L., R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck, P. Arlen, et al. 2000. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18: 3964-3973.
23. Kaufman, H. L., W. Wang, J. Manola, R. S. DiPaola, Y. J. Ko, C. Sweeney, T. L. Whiteside, J. Schlom, G. Wilding, and L. M. Weiner. 2004. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22: 2122-2132.
24. Smith, C. L., P. R. Dunbar, F. Mirza, M. J. Palmowski, D. Shepherd, S. C. Gilbert, P. Coulie, J. Schneider, E. Hoffman, R. Hawkins, et al. 2005. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113: 259-266.
25. Lindsey, K. R., L. Gritz, R. Sherry, A. Abati, P. A. Fetsch, L. C. Goldfeder, M. I. Gonzales, K. A. Zinnack, L. Rogers-Freezer, L. Haworth, et al. 2006. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12: 2526-2537.
26. Marshall, J. 2003. Carcinoembryonic antigen-based vaccines. Semin. Oncol. 30: 30-36.
27. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
28. Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J. C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145: 229-250.
29. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
30. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
31. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-365.
32. Fischer, C., F. Gudat, P. Stulz, C. Noppen, C. Schaefer, P. Zajac, M. Trutmann, T. Kocher, M. Zuber, F. Harder, et al. 1997. High expression of MAGE-3 protein in squamous-celi lung carcinoma. Int. J. Cancer 71: 1119-1121.
33. Uyttenhove, C., C. Godfraind, B. Lethe, A. Amar-Costesec, J. C. Renauld, T. F. Gajewski, M. T. Duffour, G. Warnier, T. Boon, and B. J. Van den Eynde. 1997. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer 70: 349-356.
34. Van den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173: 1373-1384.
35. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157: 1040-1052.
36. Dunn, T. B., and M. Potter. 1957. A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18: 587-601.
37. Hanke, T., C. Barnfield, E. G. Wee, L. Agren, R. V. Samuel, N. Larke, and P. Liljestrom. 2003. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84: 361-368.
38. Sundback, M., I. Douagi, C. Dayaraj, M. N. Forsell, E. K. Nordstrom, G. M. McInerney, K. Spangberg, L. Tjader, E. Bonin, M. Sundstrom, et al. 2005. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 341: 190-202.
39. Berglund, P., C. Smerdou, M. N. Fleeton, I. Tubulekas, and P. Liljestrom. 1998. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16: 562-565.
40. Chen, M., K. F. Hu, B. Rozell, C. Orvell, B. Morein, and P. Liljestrom. 2002. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J. Immunol. 169: 3208-3216.
41. Fleeton, M. N., M. Chen, P. Berglund, G. Rhodes, S. E. Parker, M. Murphy, G. J. Atkins, and P. Liljestrom. 2001. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 183: 1395-1398.
42. Berglund, P., M. N. Fleeton, C. Smerdou, and P. Liljestrom. 1999. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17: 497-507.
43. Zhou, X., P. Berglund, H. Zhao, P. Liljestrom, and M. Jondal. 1995. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA 92: 3009-3013.
44. Colmenero, P., P. Liljestrom, and M. Jondal. 1999. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther. 6: 1728-1733.
45. Ni, B., Z. Lin, L. Zhou, L. Wang, Z. Jia, W. Zhou, D. P. Diciommo, J. Zhao, R. Bremner, and Y. Wu. 2004. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene. Cancer Detect. Prev. 28: 418-425.
46. Hodge, J. W., J. P. McLaughlin, J. A. Kantor, and J. Schlom. 1997. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 15: 759-768.
47. Grosenbach, D. W., J. C. Barrientos, J. Schlom, and J. W. Hodge. 2001. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61: 4497-4505.
48. Hodge, J. W., D. W. Grosenbach, and J. Schlom. 2002. Vector-based delivery of tumor-associated antigens and T cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect. Prev. 26: 275-291.
49. Hodge, J. W., D. J. Poole, W. M. Aarts, A. Gomez Yafal, L. Gritz, and J. Schlom. 2003. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63: 7942-7949.
50. Lin, C. T., C. F. Hung, J. Juang, L. He, K. Y. Lin, T. W. Kim, and T. C. Wu. 2003. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol. Ther. 8: 559-566.
51. Mennuni, C., F. Calvaruso, A. Facciabene, L. Aurisicchio, M. Storto, E. Scarselli, G. Ciliberto, and N. La Monica. 2005. Efficient induction of T cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117: 444-455.
52. Goldberg, S. M., S. M. Bartido, J. P. Gardner, J. A. Guevara-Patino, S. C. Montgomery, M. A. Perales, M. F. Maughan, J. Dempsey, G. P. Donovan, W. C. Olson, et al. 2005. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin. Cancer Res. 11: 8114-8121.
53. Xia, D., T. Moyana, and J. Xiang. 2006. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. 16: 241-259.
54. Palmowski, M. J., E. M. Choi, I. F. Hermans, S. C. Gilbert, J. L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, et al. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168: 4391-4398.
55. Irvine, K. R., R. S. Chamberlain, E. P. Shulman, D. R. Surman, S. A. Rosenberg, and N. P. Restifo. 1997. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89: 1595-1601.
56. Elzey, B. D., D. R. Siemens, T. L. Ratliff, and D. M. Lubaroff. 2001. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94: 842-849.
57. Tan, G. S., P. M. McKenna, M. L. Koser, R. McLinden, J. H. Kim, J. P. McGettigan, and M. J. Schnell. 2005. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331: 82-93.
58. Gherardi, M. M., E. Perez-Jimenez, J. L. Najera, and M. Esteban. 2004. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. 172: 6209-6220.
59. Gilbert, S. C., V. S. Moorthy, L. Andrews, A. A. Pathan, S. J. McConkey, J. M. Vuola, S. M. Keating, T. Berthoud, D. Webster, H. McShane, and A. V. Hill. 2006. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
60. Moore, A. C., and A. V. Hill. 2004. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199: 126-143.
61. Dunachie, S. J., and A. V. Hill. 2003. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206: 3771-3779.
62. Smerdou, C., and P. Liljestrom. 1999. Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 73: 1092-1098.
63. Liljestrom, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology 9: 1356-1361.
64. Van Pel, A., E. De Plaen, and T. Boon. 1985. Selection of highly transfectable variant from mouse mastocytoma P 815. Somatic Cell Mol. Genet. 11: 467-475.
65. Gajewski, T. F., J. C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154: 5637-5648.
66. Brandle, D., J. Bilsborough, T. Rulicke, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28: 4010-4019.
67. Roberts, A. D., K. H. Ely, and D. L. Woodland. 2005. Differential contributions of central and effector memory T cells to recall responses. J. Exp. Med. 202: 123-133.
68. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576.
69. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
70. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
71. Grohmann, U., M. L. Belladonna, R. Bianchi, C. Orabona, S. Silla, G. Squillacioti, M. C. Fioretti, and P. Puccetti. 1999. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Cancer Immunol. Immunother. 48: 195-203.
72. Roder, J. C., M. L. Lohmann-Matthes, W. Domzig, R. Kiessling, and O. Haller. 1979. A functional comparison of tumor cell killing by activated macrophages and natural killer cells. Eur. J. Immunol. 9: 283-288.
73. McMichael, A. J. 2006. HIV vaccines. Annu. Rev. Immunol. 24: 227-255.
74. Rosato, A., A. Zoso, G. Milan, B. Macino, S. Dalla Santa, V. Tosello, E. Di Carlo, P. Musiani, R. G. Whalen, and P. Zanovello. 2003. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. J. Immunol. 171: 5172-5179.
75. + T cell parameters. J. Immunol. 176: 1999-2006.
76. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14631-14638.
77. Coulie, P. G., and T. Connerotte. 2005. Human tumor-specific T lymphocytes: does function matter more than number. Curr. Opin. Immunol. 17: 320-325.
78. Perez-Diez, A., P. J. Spiess, N. P. Restifo, P. Matzinger, and F. M. Marincola. 2002. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. 168: 338-347.
79. + T cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211: 214-224.
80. + T cell subsets identified by expression of IL-7 receptor a and CD62L. J. Immunol. 175: 4686-4696.
81. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763.
82. + T cell lineage commitment. Nat. Immunol. 6: 793-799.
83. Thompson, L. J., G. A. Kolumam, S. Thomas, and K. Murali-Krishna. 2006. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 177: 1746-1754.
84. Hidmark, A. S., G. M. McInerney, E. K. Nordstrom, I. Douagi, K. M. Werner, P. Liljestrom, and G. B. Karlsson Hedestam. 2005. Early α/β interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J. Virol. 79: 10376-10385.
85. Hidmark, A. S., E. K. Nordstrom, P. Dosenovic, M. N. Forsell, P. Liljestrom, and G. B. Karlsson Hedestam. 2006. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require α/β interferon signaling. J. Virol. 80: 7100-7110.
86. Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
87. Pichlmair, A., O. Schulz, C. P. Tan, T. I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5 ′-phosphates. Science 314: 997-1001.
88. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192: 1105-1113.
89. d-peptide complex explains the unique interaction of Ld with β-2 microglobulin and peptide. Proc. Natl. Acad. Sci. USA 94: 6880-6885.
90. Masopust, D., S. J. Ha, V. Vezys, and R. Ahmed. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177: 831-839.
91. Lefrancois, L. 2006. Development, trafficking, and function of memory T cell subsets. Immunol. Rev. 211: 93-103.
92. + T cells: when, where, and how. Annu. Rev. Immunol. 24: 519-540.
93. + memory T cells. Immunol. Rev. 211: 146-153.
94. Harari, A., V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T cell immunity in human virus infections. Immunol. Rev. 211: 236-254.